Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-12321 in ALK-positive Advanced Malignancies
NCT07810933Phase 2Recruiting
- Sponsor
- Shouyao Holdings
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of SY-12321 in advanced cancer, non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumor (IMT), anaplastic large cell lymphoma (ALCL), colorectal cancer (CRC), sponsored by Shouyao Holdings. Started Aug 2026; status: recruiting.
02
Drugs
SY-12321
03
Conditions
advanced cancernon-small cell lung cancer (NSCLC)inflammatory myofibroblastic tumor (IMT)anaplastic large cell lymphoma (ALCL)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07810933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07810933.